134 related articles for article (PubMed ID: 31019405)
1. A Critical Evaluation of Enoxaparin Dose Adjustment Guidelines in Children.
Dinh CN; Moffett BS; Galati M; Lee-Kim Y; Yee DL; Mahoney D
J Pediatr Pharmacol Ther; 2019; 24(2):128-133. PubMed ID: 31019405
[TBL] [Abstract][Full Text] [Related]
2. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma.
Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ
JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Pediatric Enoxaparin Dosing Protocol and the Impact on Clinical Outcomes.
Wiltrout K; Lissick J; Raschka M; Nickel A; Watson D
J Pediatr Pharmacol Ther; 2020; 25(8):689-696. PubMed ID: 33214779
[TBL] [Abstract][Full Text] [Related]
4. An Evaluation of the Appropriateness of Initial Enoxaparin Dosing Among Pediatric Patients.
Altuwayjiri A; AlDarwish A; Alshuraim R
Cureus; 2023 Nov; 15(11):e48830. PubMed ID: 38106767
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
Hicks JK; Shelton CM; Sahni JK; Christensen ML
Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
[TBL] [Abstract][Full Text] [Related]
6. Evaluation and Pharmacokinetics of Treatment Dose Enoxaparin in Hospitalized Patients With Morbid Obesity.
Thompson-Moore NR; Wanat MA; Putney DR; Liebl PH; Chandler WL; Muntz JE
Clin Appl Thromb Hemost; 2015 Sep; 21(6):513-20. PubMed ID: 25601898
[TBL] [Abstract][Full Text] [Related]
7. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
[TBL] [Abstract][Full Text] [Related]
8. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma.
Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG
JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333
[TBL] [Abstract][Full Text] [Related]
9. Effects of age and weight-based dosing of enoxaparin on anti-factor xa levels in pediatric patients.
Fung LS; Klockau C
J Pediatr Pharmacol Ther; 2010 Apr; 15(2):119-25. PubMed ID: 22477802
[TBL] [Abstract][Full Text] [Related]
10. Utility of anti-xa monitoring in children receiving enoxaparin for therapeutic anticoagulation.
Leung M; Ho SH; Hamilton DP; Wu JK; Dix DB; Wadsworth LD; Ensom MH
J Pediatr Pharmacol Ther; 2005 Jan; 10(1):43-50. PubMed ID: 23118625
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
Kruse MW; Lee JJ
Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Initial Enoxaparin Dosing and Antifactor Xa Levels in Infants Admitted to the Neonatal Intensive Care Unit.
Nagy R; Hemmelgarn T; Deptola S; Hemmann B
Biomed Hub; 2024; 9(1):54-61. PubMed ID: 38616894
[TBL] [Abstract][Full Text] [Related]
13. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
Lee YR; Vega JA; Duong HN; Ballew A
Pharmacotherapy; 2015 Nov; 35(11):1007-15. PubMed ID: 26598093
[TBL] [Abstract][Full Text] [Related]
14. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
Sanchez de Toledo J; Gunawardena S; Munoz R; Orr R; Berry D; Sonderman S; Krallman S; Shiderly D; Wang L; Wearden P; Morell VO; Chrysostomou C
Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
[TBL] [Abstract][Full Text] [Related]
15. Enoxaparin thromboprophylaxis in hospitalized obese pediatric patients.
Yim J; Jahan A; Braykov N; Murphy ND; Woods GM
Pediatr Blood Cancer; 2024 Mar; ():e30942. PubMed ID: 38486078
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Enoxaparin in Pediatric Patients.
Moffett BS; Lee-Kim Y; Galati M; Mahoney D; Shah MD; Teruya J; Yee D
Ann Pharmacother; 2018 Feb; 52(2):140-146. PubMed ID: 28962537
[TBL] [Abstract][Full Text] [Related]
17. An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review.
Ho SH; Wu JK; Hamilton DP; Dix DB; Wadsworth LD
J Pediatr Hematol Oncol; 2004 Sep; 26(9):561-6. PubMed ID: 15342982
[TBL] [Abstract][Full Text] [Related]
18. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
[TBL] [Abstract][Full Text] [Related]
19. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin.
Rowan BO; Kuhl DA; Lee MD; Tichansky DS; Madan AK
Obes Surg; 2008 Feb; 18(2):162-6. PubMed ID: 18165884
[TBL] [Abstract][Full Text] [Related]
20. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
Lin H; Faraklas I; Saffle J; Cochran A
J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]